B. M. BOELKINS ET AL.
204
greatly improve the quality of PC care within the com-
munity. Previous studies have shown the sensitivity of
PCA3 score to be lower than PSA testing, indicating that
PCA3 should not replace PSA as a screening tool [10,12,
16,17]. Instead, given its superior specificity, PCA3
score could be used to stratify men with elevated PSA
based on risk of PC. The addition of PCA3 score to PSA
and other clinical parameters within a nomogram pre-
dicting PC and high-grade PC has been proposed and
warrants further validation [21].
5. Conclusion
Measurement of PCA3 score in a community-based uro-
logic practice successfully reduced the number of pros-
tate biopsies performed in response to PSA testing by
78%. At a median of >2 year follow-up of these patients,
78% of these men also avoided subsequent biopsy. Con-
versely, PC was detected in 64% of men undergoing PB
for a PCA3 score > 35. Measurement of PCA3 score in
lieu of PB for men with elevated PSA has the potential to
reduce unnecessary prostate cancer diagnosis and treat-
ment if used more widely.
6. Acknowledgements
The authors would like to thank Kevin Hinton, Bonnie
Dykstra and Maureen Gebben for assistance with re-
search activities.
REFERENCES
[1] V. A. Moyer, on Behalf of the US Preventive Services
Task Force, “Screening for Prostate Cancer: US Preven-
tive Services Task Force Recommendation Statement,”
Annals of Internal Medicine, Vol. 157, No. 2, 2012, pp.
120-134.
[2] R. J. Babaian, A. Toi, K. Kamoi, P. Troncoso, J. Sweet, R.
Evans, et al., “A Comparative Analysis of Sextant and an
Extended 11-Core Multisite Directed Biopsy Strategy,”
Journal of Urology, Vol. 163, No. 1, 2000, pp. 152-157.
doi:10.1016/S0022-5347(05)67993-1
[3] C. K. Naughton, D. C. Miller, D. E. Mager, D. K. Orn-
stein and W. J. Catalona, “A Prospective Randomized
Trial Comparing 6 versus 12 Prostate Biopsy Cores: Im-
pact on Cancer Detection,” Journal of Urology, Vol. 164,
No. 2, 2000, pp. 388-392.
doi:10.1016/S0022-5347(05)67367-3
[4] J. C. Presti Jr., J. J. Chang, V. Bhargava and K. Shino-
hara, “The Optimal Systematic Prostate Biopsy Scheme
Should Include 8 Rather than 6 Biopsies: Results of a
Prospective Clinical Trial,” Journal of Urology, Vol. 163,
No. 1, 2000, pp. 163-167.
doi:10.1016/S0022-5347(05)67995-5
[5] B. Djavan, V. Ravery, A. Zlotta, P. Dobronski, M. Do-
brovits, M. Fakhari, et al., “Prospective Evaluation of
Prostate Cancer Detected on Biopsies 1, 2, 3 and 4: When
Should We Stop?” Journal of Urology, Vol. 166, No. 5,
2001, pp. 1679-1683.
doi:10.1016/S0022-5347(05)65652-2
[6] G. I. Pinkhasov, Y. K. Lin, R Palmerola, P. Smith, F.
Mahon, M. G. Kaag, et al., “Complications Following
Prostate Needle Biopsy Requiring Hospital Admission or
Emergency Department Visits—Experience from 1000
Consecutive Cases,” BJU International, Vol. 110, No. 3,
2012, pp. 369-374.
doi:10.1111/j.1464-410X.2011.10926.x
[7] M. J. Bussemakers, A. van Bokhoven, G. W. Verhaegh, F.
P. Smit, H. F. Karthaus, J. A. Schalken, et al., “DD3: A
New Prostate-Specific Gene, Highly Overexpressed in
Prostate Cancer,” Cancer Research, Vol. 59, No. 23,
1999, pp. 5975-5979.
[8] J. B. de Kok, G. W. Verhaegh, R. W. Roelofs, D. Hessels,
L. A. Kiemeney, T. W. Aalders, et al., “DD3(PCA3), a
very Sensitive and Specific Marker to Detect Prostate
Tumors,” Cancer Research, Vol. 62, No. 9, 2002, pp.
2695-2698.
[9] D. Hessels, M. P. van Gils, O. van Hooij, S. A. Jannink, J.
A. Witjes, G. W. Verhaegh, et al., “Predictive Value of
PCA3 in Urinary Sediments in Determining Clinico-
Pathological Characteristics of Prostate Cancer,” Prostate,
Vol. 70, No. 1, 2010, pp. 10-16. doi:10.1002/pros.21032
[10] R. R. Goode, S. J. Marshall, M. Duff, E. Chevli and K. K.
Chevli, “Use of PCA3 in Detecting Prostate Cancer in
Initial and Repeat Prostate Biopsy Patients,” Prostate,
Vol. 73, No. 1, 2012, pp. 48-53.
[11] M. J. Roobol, F. H. Schroder, E. D. Crawford, S. J.
Freedland, A. O. Sartor, N. Fleshner, et al., “A Frame-
work for the Identification of Men at Increased Risk for
Prostate Cancer,” Journal of Urology, Vol. 182, No. 5,
2009, pp. 2112-2120. doi:10.1016/j.juro.2009.07.018
[12] J. Groskopf, S. M. Aubin, I. L. Deras, A. Blase, S. Bod-
rug, C. Clark, et al., “APTIMA PCA3 Molecular Urine
Test: Development of a Method to Aid in the Diagnosis
of Prostate Cancer,” Clinical Chemistry, Vol. 52, No. 6,
2006, pp. 1089-1095. doi:10.1373/clinchem.2005.063289
[13] J. I. Epstein, D. W. Chan, L. J. Sokoll, P. C. Walsh, J. L.
Cox, H. Rittenhouse, et al., “Nonpalpable Stage T1c
Prostate Cancer: Prediction of Insignificant Disease Using
Free/Total Prostate Specific Antigen Levels and Needle
Biopsy Findings,” Journal of Urology, Vol. 160, No. 6,
1998, pp. 2407-2411.
[14] M. C. Wang, L. A. Valenzuela, G. P. Murphy and T. M.
Chu, “Purification of a Human Prostate Specific Anti-
gen,” Investigative Urology, Vol. 17, No. 2, 1979, pp.
159-163.
[15] M. Kuriyama, M. C. Wang, C. L. Lee, C. S. Killian, L. D.
Papsidero, H. Inaji, et al., “Multiple Marker Evaluation in
Human Prostate Cancer with the Use of Tissue-Specific
Antigens,” Journal of the National Cancer Institute, Vol.
68, No. 1, 1982, pp. 99-105.
[16] W. H. Cooner, B. R. Mosley, C. L. Rutherford Jr., J. H.
Beard, H. S. Pond, W. J. Terry, et al., “Prostate Cancer
Detection in a Clinical Urological Practice by Ultrasono-
graphy, Digital Rectal Examination and Prostate Specific
Antigen,” Journal of Urology, Vol. 143, No. 6, 1990, pp.
Copyright © 2013 SciRes. OJU